8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 26, 2024

INHIBIKASE THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-39676	26-3407249
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3350 Riverwood Parkway SE, Suite 1900
Atlanta, Georgia	30339
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s Telephone Number, Including Area Code: (678) 392-3419

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	IKT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On April 29, 2024, Inhibikase Therapeutics, Inc. (the “Company”) utilized a corporate presentation which may be used in presentations to investors and analysts from time to time. A copy of the presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information furnished in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K is not incorporated by reference into any filings of the Company made under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in the filing unless specifically stated so therein.

Item 8.01 Other Events.

On April 26, 2024, the Company received a notice of a demand for arbitration with the American Arbitration Association from Pivot Holding LLC (“Pivot”), that alleges to be a successor in interest to Sphaera Pharma Pte. Ltd. (“Sphaera”), in connection with the Collaborative Research and Development Agreement dated February 29, 2012, as amended, between the Company and Sphaera. Pivot alleges breach of contract by the Company for failure to pay milestone payments and seeks damages of $1.625 million in milestone payments plus interest. The Company believes that Pivot’s claims are without merit and that the Company hasn’t owed and doesn’t owe any milestone payments to Pivot. The Company intends to vigorously dispute Pivot’s claims and assert counterclaims against Pivot.

Forward-Looking Statements

This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause the Company’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to successfully defend ourselves and assert counterclaims in the arbitration proceeding commenced by Pivot, to enroll and complete the 201 Trial evaluating risvodetinib in untreated Parkinson’s disease, to successfully apply for and obtain FDA approval for IkT-001Pro in blood and stomach cancers or other indications, to successfully conduct clinical trials that are statistically significant, whether results from our animal studies may be replicated in humans, our need for additional capital especially to conduct the 12 month extension study of our 201 trial, the substantial doubt regarding our ability to continue as a going concern, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number	Description
99.1	Presentation of Inhibikase Therapeutics, Inc.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 30, 2024	INHIBIKASE THERAPEUTICS, INC.
	By:	/S/ MILTON H. WERNER
		Milton H. Werner, Ph.D.
		President and Chief Executive Officer

EX-99.1

Exhibit 99.1 2Q24 | BUSINESS PRESENTATION Clinical Development of Disease-Modifying Therapeutics for Neurodegenerative Disease, Cancer and Cardiopulmonary Disease Inhibikase.com : IKT

DISCLAIMER This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This presentation contains information that may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Inhibikase Therapeutics, Inc. (the “Company” or “we”) intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in those sections. Generally, we have identified such forward-looking statements by using the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “target,” “forecast,” “aim,” should, “will,” may”, “continue” and similar expressions. Such statements are subject to a number of assumptions, risks and uncertainties which may cause actual results, performance or achievements to be materially different from those anticipated in these forward-looking statements. You should read statements that contain these words carefully because they discuss future expectations and plans which contain projections of future clinical studies, regulatory approvals, product candidate development, results of operations or financial condition or state other forward-looking information. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements are not historical facts, but instead represent only the Company’s beliefs regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Management believes that these forward-looking statements are reasonable as of the time made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Company's historical experience and our present expectations or projections. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in the Company’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly Form 10-Q, including under the caption Risk Factors”. We do not intend our use or display of other entities’ names, trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. Inhibikase.com • : IKT 2

OFFERING SUMMARY Inhibikase Therapeutics, Inc. (“IKT” or the “Company”) ISSUER: Nasdaq Capital Market: IKT EXCHANGE/SYMBOL: Best Efforts S-1 Follow-on OFFERING TYPE: Up to $13.0 Million GROSS PROCEEDS: Units consisting of one share of Common Stock (or one Pre-Funded Warrant in lieu SECURITIES TO BE thereof), and one Warrant to purchase one share of common stock OFFERED: To extend the 201 trial for Risvodetinib (IkT-148009) up to an additional 12 months, ANTICIPATED USE OF support expansion of their biomarker program and ancillary studies required for Phase PROCEEDS: 3 entry and other general corporate purposes Maxim Group LLC SOLE PLACEMENT AGENT: Week of April 29, 2024 ANTICIPATED PRICING: Inhibikase.com • : IKT 3

MULTI-THERAPEUTIC PIPELINE OF KINASE INHIBITOR THERAPEUTICS Developing innovative medicines across the therapeutic spectrum • Multi-therapeutic pipeline across neurodegenerative disease, cancer and cardiopulmonary disease • Risvodetinib (IkT-148009): Selective c-Abl inhibitor. Phase 2 ongoing to evaluate disease modification in Parkinson’s disease. Phase 2 201 trial, 77% enrolled in the U.S. 12-week trial planned to be extended by up to 12 additional months, subject to additional resources. Blinded functional and biomarker data support continuation and expansion of trial. $12B+ 1 global addressable market. • IkT-001Pro: Prodrug of imatinib mesylate. Phase 3 complete in blood and stomach cancers, Phase 2/3 ready in 2 Pulmonary Arterial Hypertension. $7B+ global addressable market. • Robust patent portfolio with compositions of matter protected to 2033 (IkT-001Pro) and 2036 (risvodetinib). • Orphan designations: Rivsodetinib in Multiple System Atrophy, IkT-001Pro in multiple oncology indications and pulmonary arterial hypertension. • Cash/cash equivalent runway into 1Q25. • Highly-experienced management team, consultants, Board of Directors and Scientific Advisory Board. 1 ; 2 Vision Research, 2022 ; From Biomedtracker (Citeline Commercial), 2024 (https://www.biomedtracker.com/indicationreport.cfm?indid=245#PipelineChart) Inhibikase.com • : IKT 4

COMPANY HIGHLIGHTS: MULTI-THERAPEUTIC PIPELINE Multi-Indication Pipeline in Neurodegeneration, Oncology and Non-oncology Indications 1 CLINICAL DEVELOPMENT (1). ‘Clinical Development’ progress PRECLINICAL bars represent the current state of the DRUG TARGET DRUG CANDIDATE MODALITY DISEASE INDICATION PHASE 1/1B PHASE 2 PHASE 3 DEVELOPMENT indicated programs. Blue arrows represent completed or in progress studies; white arrows represent planned Neurodegeneration approaches for future clinical studies. Parkinson’s Disease: (2). Four indications will be pursued for c-Abl Risvodetinib Small molecule Treatment Naive IkT-148009 in PD, which will be pursued through studies of treatment naïve and early-stage patients, Parkinson’s Disease: c-Abl Risvodetinib Small molecule including their GI complications. MSA is 4 Indications Pursued Early Stage an orphan, aggressive form of Through 2 INDs. Shares Parkinson’s-like disease to enter clinical 2 Same Phase 1 and 2 c-Abl Risvodetinib Small molecule Neurogenic Constipation development at Phase 2 following completion and positive outcomes from animal model studies of IkT-148009 in c-Abl Risvodetinib Small molecule Dysphagia prophylactic and therapeutic dosing studies. Pursued through open c-Abl Risvodetinib Small molecule Multiple System Atrophy IND in the US and future EMA filing in EU Oncology BCR-Abl IkT-001Pro Small molecule Stable-phase CML (orphan indication) 505(b)(2) Path to Market Cardiopulmonary disease IND to be filed May, 2024 to c-Abl IkT-001Pro Small molecule Pulmonary Arterial Hypertension initiate Phase 2/3 study Research c-Abl IkT-148x, BIP4-7 Small molecule Dementia with Lewy Body c-Abl IkT-148x, BIP4-7 Small molecule Multiple System Atrophy Inhibikase.com • : IKT 5

Parkinson’s and Related Disorders Parkinson’s Disease Market & Strategy Inhibikase.com • : IKT 6

THE MARKET: DISEASE-MODIFICATION WILL TRANSFORM TREATMENT PARADIGM 1 Parkinson’s disease and MSA in the U.S. Parkinson’s: Slowly Progressing MSA: Rapidly Progressing 1/3 of a Patient’s Lifespan to death = 25 years 1/10 of a Patient’s Lifespan to death = 8 years Global treatment sales for PD by 2030 are expected 90,000 38,000 15,000 -50,000 to exceed New Cases / Year Deaths / Year Cases 930,000 – 1,200,000 Orphan Disease $12.2 BILLION 1 U.S. Patients Vision Research, 2022 60 55 Current treatments Average Age Of Onset Average Age Of Onset cannot alter course of Parkinson’s disease Co-morbid indications MSA has no beneficial Men twice treatments as likely as The country with the highest women to diagnosed prevalence is contract 47% 30% 35% 36% THE U.S. disease Arthritis Heart/Circulatory Psychosis Dementia Vision Research, 2022 1 Parkinson’s Disease Foundation Decisions Resources 2016, Lewin Report in the Economic Burden and Future Impact of Parkinson’s disease, 2019. Inhibikase.com • : IKT 7

1 SEARCHING FOR THE ROLE OF THE MISFOLDED PROTEIN IN MAJOR CNS DISEASE Different proteins, similar pathological effect b-amyloid and Tau in Alzheimer’s a-synuclein in PD, MSA, DLB What role does the misfolded protein play? 1 Nat. Neurosci. 21: 1332-1340 (2018) Inhibikase.com • : IKT 8

EXTERNAL OR INTERNAL AS A SITE OF TARGETING? antibody or Clearance of pathological plaque unknown dis-aggregator targets plaque NOT restorative outside affected neurons mechanistic inhibitors Does clear pathological plaques like risvodetinib CAN BE restorative target plaque inside affected neurons 1 Ø Risvodetinib targets an enzyme, c-Abl, inside the neurons at the site of disease initiation 1 Werner and Olanow , Mov Disorders 2021, doi: 10.1002/mds.28858 Karuppagounder, Werner, et al., Sci Transl. Med 2023 doi: 10.1126/scitranslmed.abp9352 Inhibikase.com • : IKT 9

RISVODETINIB MODIFIES PARKINSON'S DISEASE c-Abl inhibition by Risvodetinib restores lost function in Validated Animal 1 Models of Parkinson’s disease a Neurodegeneration Motor Dysfunction -Synuclein Toxicity Neuroinflammation preserves restores clears suppresses as much as 85% as much as 90% to baseline in the to near baseline of brain neurons of lost function organs of disease in the organs of disease 1 Werner and Olanow , Mov Disorders 2021, doi: 10.1002/mds.28858 Karuppagounder, Werner, et al., Sci Transl. Med 2023 doi: 10.1126/scitranslmed.abp9352 Inhibikase.com • : IKT 10

The 201 Trial evaluating Risvodetinib in Untreated Parkinson’s Disease Inhibikase.com • : IKT 11

The 201 TRIAL: TRIAL DESIGN AND PATIENT FLOW or 92 As of April 23, 2024 or Inhibikase.com • : IKT 12

THE 201 TRIAL; POSSIBLY RISVODETINIB-RELATED ADVERSE EVENTS AS OF APRIL 23, 2024 Adverse Event Severity (# Occurrences) Gastrointestinal Nausea (1) Mild Vomiting (3) Mild (3) 25 AEs occurred in 17 of Gas/Cramps (2) Mild (1)/Moderate (1) 92 enrolled participants Heartburn (1) Mild Diarrhea (3) Mild Constipation (1) Mild Cardiovascular Abnormal ECG (2) Mild Orthostatic hypotension (2) Mild Laboratory Elevated lipase (1) Mild Elevated creatinine (1) Mild Psychological/Neurological Irritability (1) Mild Headache (2) Mild Increase energy (1) Mild Worsening Parkinsonism (1) Moderate (non-compliant dosing) Musculoskeletal Fatigue (2) Mild Rash (1) Mild Inhibikase.com • : IKT 13

201 TRIAL: EARLY UNBLINDED OBSERVATIONS Functional Assessment: Universal Parkinson’s Disease Rating Scale (MDS-UPDRS) Part 2: Measures ability to do everyday activities (teeth brushing, dressing on your own, etc.) Part 3: Measures ability to do walk, stand, balance Improvement occurs when numbers decrease; Worsening occurs when numbers increase Mean Changes From Baseline 1 End of Study 50 mg 100 mg 200 mg Placebo N=3 N=2 N=3 N=3 MDS-UPDRS -0.33 0 -4.33 0 Part 2 MDS-UPDRS 2 -1.3 -4.33 1.7 Part 3 Part 2 + Part 3 1.67 -1.3 -8.7 1.7 -10.4 1 Given small sample size, we do not yet conclude that a clinical benefit has been achieved. Inhibikase.com • : IKT 14

THE 201 TRIAL; BIOMARKER ANALYSIS ONGOING Blood and CSF biomarkers Tissue-derived biomarkers Tissue biomarkers may indicate clearance of plaque Spinal fluid biomarkers may confirm proper diagnosis of pathology in the 201 Trial. Proprietary antibody against disease in the 201 Trial. phosphorylated alpha-synuclein will use this method to report on target engagement as well. Inhibikase.com • : IKT 15

INHIBITION OF C-Abl MAY HAVE A WIDER ROLE IN OTHER DISEASES Risvodetinib in other neurodegenerative disease 1 MSA ALS Alzheimer’s J Neurol Sci. 2018;393:80-82 Prog Neurobiol. 2021;202:102031 Autophagy. 2021;17(5):1278-1280. Sci Transl Med. 2017;9(391):eaaf3962 J Biol Chem. 2020 ;295(23):7905-7922 Front Cell Neurosci. 2015 9;9:203 Front Cell Neurosci. 2019;13:526 PLoS One. 2012;7(9):e46185 Biochim Biophys Acta Mol Basis Dis. 2018; 1864(4 Pt A):1148-1159 Biomol Struct Dyn. 2017;35(4):883-896 J Alzheimers Dis. 2016 ;54(3):1193-1205 PLoS One. 2014 ;9(3):e92309 Curr Alzheimer Res. 2011;8(6):643-51. Neurobiol Aging. 2011;32(7):1249-61. J Alzheimers Dis. 2011;25(1):119-33. J Alzheimers Dis. 2010;19(2):721-33. J Alzheimers Dis. 2009;18(1):1-9 J Alzheimers Dis. 2009;17(2):409-22 Brain. 2008;131(Pt 9):2425-42 Neurobiol Dis. 2004;17(2):326-36 Proc Natl Acad Sci U S A. 2003;100(21):12444-9. 1 Marmion, Werner, Kordower et al, (2021) Neurobiol Dis 148:105184 Inhibikase.com • : IKT 16

IkT-001Pro for Treatment of Blood and Stomach Cancers and Cardiopulmonary Disease Inhibikase.com • : IKT 17

IkT- 001Pro INNOVATION IkT-001Pro releases the active ingredient imatinib only in blood 4-carbon atom linker imatinib linker gut wall + pH 2-6 pH 7 (blood) (stomach, ileum, duodenum) Lifetime in blood < 10 min Inhibikase.com • : IKT 18

IkT- 001Pro IS A SMALL MOLECULE C-Abl INHIBITOR IkT-001Pro has less toxicity in non-human primate: Potentially Safer Alternative to Imatinib Mesylate Measurement of IkT-001Pro in Non-Human Primates RESULTS SUGGEST THAT: No Adverse Event Level Cmax Tmax AUC 0-T (mg/kg) ü Achieve dose flexibility, (mean, ng/mL) (mean, h) (mean, ng-h/mL) NOAEL including use of higher dosing due to lower AEs Imatinib 176/206 4/3 1540/1960 15 1 (Day 91) (M/F) (M/F) (M/F) ü Suppress GI and other adherence-related adverse 2 IkT-001Pro 400/318 5.3/3.7 5220/3890 75 events (Day 28) (M/F) (M/F) (M/F) 1 FDA summary data for approval 21-335 2 IkT IND #135167 ▲ ▲ NO ADVERSE EVENTS Up to 3.4x Up to 3.4x increased exposure higher dose of imatinib delivered as 001Pro Inhibikase.com • : IKT 19

TRIALS IN BIOEQUIVALENCE AND SUPERIORITY Clinical Development of IkT-001Pro: Summary § Phase 3 Complete in Blood and Stomach Cancers Ø Competes against generic imatinib mesylate 1 Ø≈$300M market US § Phase 2/3 Ready in Pulmonary Arterial Hypertension Ø Proven to be disease-modifying, but Phase 3 needs to be repeated due to 2 safety concerns 10 years ago Ø Developing to compete with sotatercept, marketed as Winrevair (approved March, 2024) 3 4 4 Ø $4.6B market US , $7B+ global, 5.3% CAGR 1 ISI retail sales data 2016-2020 2 Circulation 2013;127:1128-1138 3 From Biomedtracker (Citeline Commercial), 2024 (https://www.biomedtracker.com/indicationreport.cfm?indid=245#PipelineChart) 4 Precedence Research, 2023 (https://www.linkedin.com/pulse/pulmonary-arterial-hypertension-market-prathamesh-sakpal-lvrfc/) Inhibikase.com • : IKT 20

Selected Financial Data IIn nh hib ibik ika as se e..c co om m • • :: IK IKT T 21 21

COMPANY HIGHLIGHTS Selected Financial and Stock Data Capitalization Table April 15, 2024 Balance Sheet December 31, 2023 Common Shares Outstanding 6,476,844 Current Assets: Options (WAEP: $10.33) 985,280 Cash, Cash Equivalents, Warrants (WAEP: $7.64) 2,266,136 $13,252,052 Marketable Securities Prepaid research and Fully Diluted Shares Outstanding 9,728,260 $219,817 development Prepaid expenses and other $739,179 current assets Total Current Assets $14,211,048 Total Current Liabilities $3,438,601 Total Working Capital $10,772,447 Inhibikase.com • : IKT 22

ABOUT US / EXECUTIVES Management Team with Deep Experience in Drug Development and Commercialization Milton Werner, PhD Garth Lees-Rolfe C. Warren Olanow, MD, President & CEO Chief Financial Officer Medical Consultant and Chief Executive Officer of Clintrex Research Corporation. Previously, Dr. Werner served as Director of Previously served as our Vice Research at Celtaxsys. From September 1996 until President of Finance from Dr. Olanow is the former Henry P. and Georgette Goldschmidt Professor and Chairman of June 2007, Dr. Werner was a Head of the November 2022 to March 2024. the Department of Neurology at the Mount Sinai School of Medicine Prior to joining Mount Laboratory of Molecular Biophysics at The Prior to Inhibikase served as the Sinai, he served on the faculties of McGill University, Duke University, and the University of Rockefeller University in New York City. Throughout Vice-President, Finance for F- South Florida. He is the former President of the Movement Disorder Society, past President of the International Society of Motor Disturbances, and former Treasurer of the American his scientific career, Dr. Werner has been an Star, Inc., a publicly traded global Neurological Association. He has served on the executive committee of the Michael J. Fox innovator integrating chemistry, physics, and biology clinical-stage biotech company. Foundation Scientific Advisory Board, and he is the former Chairman of the Scientific into a comprehensive approach to solving problems Prior to his corporate work, spent 16 Advisory Board of the Bachmann-Strauss Parkinson Foundation and of the Dystonia in medicine. Dr. Werner is the author or co-author of years in public practice mostly with Foundation. Dr. Olanow is the former Co-Editor-in-Chief of the journal Movement Disorders. more than 70 research articles, reviews, and book Ernst & Young, lastly as a Senior Dr. Olanow received his medical degree from the University of Toronto, performed his chapters and has given lectures on his research Manager. He is a licensed Certified neurology training at the New York Neurological Institute at Columbia Presbyterian Medical work throughout the world. Public Accountant in the state of Center at Columbia University, and undertook postgraduate studies in neuroanatomy at Massachusetts and a licensed Columbia University and authored more than 600 articles in the field of neurodegeneration. Chartered Accountant of Australia and New Zealand. Inhibikase.com • : IKT 23

ABOUT US / BOARD OF DIRECTORS Mr. Dennis Berman Ms. Gisele Dion Dr. Roy Freeman, MD Dr. Paul Grint, MD • Co-founder, board member, and/or • Chief Accounting Officer of Alnylam • Professor of Neurology at the Harvard • 20+ years experience in biologics and seed investor in many private Pharmaceuticals since November, 2023 Medical School and Director of the small-molecule research and biotechnology and technology • Senior Vice President, Chief Accounting Center for Autonomic and Peripheral development, including the successful companies, five of which have gone Officer and Corporate Controller at Takeda Nerve Disorders in the Department of approval and commercialization of public. Pharmaceutical Ltd Neurology at Beth Israel Deaconess products in the infectious diseases, • Currently serves as the President of • Senior Advisor to the Chief Financial Medical Center immunology, and oncology therapeutic Molino Ventures, LLC a board Officer of Takeda Pharmaceutical Ltd. • Former chairman of the World areas. advisory and venture capital firm and • Vice President, Chief Accounting Officer Federation of Neurology research • Director of Amplyx Pharmaceuticals was co-founder and Executive Vice and Corporate Controller at Shire group on the autonomic nervous and Synedgen. President of Corporate Development Pharmaceuticals LLC, system, former President of the • Served in senior management roles at of Tocagen. • Corporate Controller and Senior Director American Autonomic Society, and Cerexa, Forest Laboratories, • Seed investor, co-founder, and/or of Technical Accounting at Biogen Inc., former chairman of the Autonomic Kalypsys, Pfizer, IDEC board member of Intervu, Viagene, • Currently Director and Audit Committee Section of the American Academy of Pharmaceuticals, and Schering- Kintera, Inc., Gensia, Calabrian Chair, Cytek Biosciences, Inc. Neurology. Plough Corporation. • Staff Member of the Financial Accounting • Editor-in-Chief of Autonomic • Fellow of the Royal College of Standards Board (FASB) Neuroscience: Basic and Clinical and Pathologists and a medical degree • Audit Advisor Group Member for the on the editorial boards of The Clinical from St. Bartholomew’s Hospital Dr. Milton H. Werner, PhD Pharmaceutical Research and Journal of Pain, Pain: Clinical College, University of London. • President & CEO, Inhibikase Manufacturers of America (PhRMA). Updates, and Clinical Autonomic Therapeutics, Inc. • B.S. in Accounting and Management Research. Information Systems from Fairfield • Serial founder of several companies in University pain and neurodegenerative disease and is on the scientific advisory boards of many large and small pharmaceutical and biotechnology companies. Inhibikase.com • : IKT 24

ABOUT US / INDUSTRY-LEADING ADVISORS Dr. Valina Dawson, PhD Dr. Karl Kieburtz, MD, MPH Dr. Robert Hauser, MD Neurodegeneration and Stem Cell Programs, Institute for Cell Robert J. Joynt Professor in Neurology, Senior Associate Dean for Professor of Neurology, University of Engineering, Departments of Neurology and Physiology Clinical Research, Director of the Clinical &Translational Science South Florida College of Medicine - The Johns Hopkins University School of Medicine Institute, Founder Center for Human Experimental Therapeutics Director USF Parkinson’s Disease and (CHET)- University of Rochester Medical Center Movement Disorders Center President Clintrex Research Corporation Dr. Warren Olanow, MD, FRCPC Henry P. and Georgette Goldschmidt Professor and Chairman Dr. Jeffrey Kordower, PhD Dr. Jay Pasricha, MBBS, MD Emeritus, Mount Sinai School of Medicine Founding Director ASU-Banner Neurodegenerative CEO, Clintrex Research Corporation Director, Johns Hopkins Center for Neurogastroenterology Disease Research Center (NDRC) Professor of Medicine The Charlene and J. Orin Edson Distinguished Director at the Biodesign Institute Professor of Life Sciences Arizona State University Dr. Ken Marek President and Senior Scientist, Institute of Neurodegenerative Disorders Dr. Ted Dawson, MD, PhD Neurodegeneration and Stem Cell Programs, Institute for Cell Engineering, Departments of Neurology, Physiology, Pharmacology, and Molecular Sciences - The Johns Hopkins University School of Medicine Inhibikase.com • : IKT 25

XML

Document and Entity Information	Apr. 26, 2024
Cover [Abstract]
Amendment Flag	false
Entity Central Index Key	0001750149
Document Type	8-K
Document Period End Date	Apr. 26, 2024
Entity Registrant Name	INHIBIKASE THERAPEUTICS, INC.
Entity Incorporation State Country Code	DE
Entity File Number	001-39676
Entity Tax Identification Number	26-3407249
Entity Address, Address Line One	3350 Riverwood Parkway SE
Entity Address, Address Line Two	Suite 1900
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30339
City Area Code	(678)
Local Phone Number	392-3419
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, $0.001 par value
Trading Symbol	IKT
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Entity Ex Transition Period	false